PROGRAM CHAIRS
David Lang, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Department of Allergy and Clinical Immunology
Cleveland Clinic
Cleveland, OH
Gil Yosipovitch, MD
Professor, Stiefel Chair of Medical Dermatology
Director Miami Itch Center
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, FL
PROGRAM OVERVIEW
Dermatologists are insufficiently familiar with the clinical phenotypical presentations and symptoms and disease characteristics of CSU, which leads to ongoing delays in diagnosis, poor prognosis, and negatively impacts on patient’s quality of life. Uncontrolled cases of CSU continue to persist despite treatment with antihistamines and oral corticosteroids; and strategies for selecting and sequencing treatment per evidence-based guidelines and patient specific factors, are suboptimal—leading to less favorable patient outcomes.
TARGET AUDIENCE
This program will meet the educational needs of dermatologists who diagnose, treat, and/or manage patients with CSU.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Facilitate prompt CSU diagnosis through identification of the clinical symptoms and associated biomarker testing
- Review the most recent clinical evidence for emerging and investigational biologic therapies in the treatment of CSU
- Understand evidence-based strategies for treatment selection considering clinical guidelines and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| David Lang, MD | Discloses that he has received consulting fees from: Sanofi-Regeneron, Novartis, Genentech, and AstraZeneca. He participated in a speakers bureau for Sanofi-Regeneron and AstraZeneca. He has received fees for non-CME/CE services from Medscape. |
| Gil Yosipovitch, MD | Discloses that he has received consulting fees from: Abbvie, Arcutis, Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Sanofi, and Vifor. He has also done contracted research with: Eli Lilly, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex Therapeutics. He has received grants/research funding from: Regeneron Pharmaceuticals, and Sanofi. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: April 30, 2024
EXPIRATION DATE: April 30, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Gil Yosipovitch, MD
Professor, Stiefel Chair of Medical Dermatology
Director Miami Itch Center
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, FL
PROGRAM OVERVIEW
Dermatologists are insufficiently familiar with the clinical phenotypical presentations and symptoms and disease characteristics of CSU, which leads to ongoing delays in diagnosis, poor prognosis, and negatively impacts on patient’s quality of life. Uncontrolled cases of CSU continue to persist despite treatment with antihistamines and oral corticosteroids; and strategies for selecting and sequencing treatment per evidence-based guidelines and patient specific factors, are suboptimal—leading to less favorable patient outcomes.
TARGET AUDIENCE
This program will meet the educational needs of dermatologists who diagnose, treat, and/or manage patients with CSU.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Review the most recent clinical evidence for emerging and investigational biologic therapies in the treatment of CSU
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Gil Yosipovitch, MD | Discloses that he has received consulting fees from: Abbvie, Arcutis, Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Sanofi, and Vifor. He has also done contracted research with: Eli Lilly, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex Therapeutics. He has received grants/research funding from: Regeneron Pharmaceuticals, and Sanofi. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Gil Yosipovitch, MD
Professor, Stiefel Chair of Medical Dermatology
Director Miami Itch Center
Dr Phillip Frost Department of Dermatology and Cutaneous Surgery
Miller School of Medicine
University of Miami
Miami, FL
PROGRAM OVERVIEW
Dermatologists are insufficiently familiar with the clinical phenotypical presentations and symptoms and disease characteristics of CSU, which leads to ongoing delays in diagnosis, poor prognosis, and negatively impacts on patient’s quality of life. Uncontrolled cases of CSU continue to persist despite treatment with antihistamines and oral corticosteroids; and strategies for selecting and sequencing treatment per evidence-based guidelines and patient specific factors, are suboptimal—leading to less favorable patient outcomes.
TARGET AUDIENCE
This program will meet the educational needs of dermatologists who diagnose, treat, and/or manage patients with CSU.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Understand evidence-based strategies for treatment selection considering clinical guidelines and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Gil Yosipovitch, MD | Discloses that he has received consulting fees from: Abbvie, Arcutis, Escient Health, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Sanofi, and Vifor. He has also done contracted research with: Eli Lilly, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex Therapeutics. He has received grants/research funding from: Regeneron Pharmaceuticals, and Sanofi. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
David Lang, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Department of Allergy and Clinical Immunology
Cleveland Clinic
Cleveland, OH
CONTRIBUTOR
Barbara Bergsten
Chagrin Falls, OH
PROGRAM OVERVIEW
Dermatologists are insufficiently familiar with the clinical phenotypical presentations and symptoms and disease characteristics of CSU, which leads to ongoing delays in diagnosis, poor prognosis, and negatively impacts on patient’s quality of life. Uncontrolled cases of CSU continue to persist despite treatment with antihistamines and oral corticosteroids; and strategies for selecting and sequencing treatment per evidence-based guidelines and patient specific factors, are suboptimal—leading to less favorable patient outcomes.
TARGET AUDIENCE
This program will meet the educational needs of dermatologists who diagnose, treat, and/or manage patients with CSU.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Facilitate prompt CSU diagnosis through identification of the clinical symptoms and associated biomarker testing
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of .25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| David Lang, MD | Discloses that he has received consulting fees from: Sanofi-Regeneron, Novartis, Genentech, and AstraZeneca. He participated in a speakers bureau for Sanofi-Regeneron and AstraZeneca. He has received fees for non-CME/CE services from Medscape. |
| Barbara Bergsten | Has nothing to disclose |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
